Vaccine Advisory Committee Puts Off Decision on Newborn Hepatitis B Shots Amid Controversy
The Advisory Committee on Immunization Practices, led by US Health Secretary Robert F. Kennedy Jr., has delayed a decision on whether newborns should receive the hepatitis B vaccine on their first day of life, citing concerns about voting language and limited safety studies.
For decades, the government has advised that all babies be vaccinated against hepatitis B at birth, a strategy widely regarded as a public health success in preventing thousands of illnesses. However, Kennedy's committee is now considering whether to recommend the birth dose only for babies whose mothers test positive for the virus, which would mark a return to a strategy abandoned over three decades ago.
The move has sparked controversy among medical groups and experts, who argue that the delay could lead to increased cases of chronic hepatitis B infections in infants. According to the Centers for Disease Control and Prevention (CDC), 90% of infants who contract hepatitis B go on to develop chronic infections.
The committee's decision is also seen as a departure from established guidelines, which advise a dose within 24 hours of birth for all medically stable infants weighing at least 4.4 pounds. The new language, which would be voted on Friday, suggests that vaccination series should begin when the child is 2 months old if parents decide not to get a birth dose.
Kennedy's leadership of the committee has been criticized by medical groups, who argue that his anti-vaccine stance and appointment of several anti-vaccine voices to the panel have compromised the agency's credibility. The committee has made several decisions in recent months that have angered major medical groups, including recommending the removal of a preservative from flu vaccines and restricting a combination shot that protects against multiple diseases.
The delay in making a decision on hepatitis B shots comes as the US is experiencing a surge in vaccine-preventable diseases, including measles and COVID-19. Experts warn that the move could embolden anti-vaccine groups and undermine public health efforts to protect vulnerable populations.
"It's like watching a train wreck in slow motion," said Dr. Jason M. Goldman, president of the American College of Physicians. "You know it's going to end badly, but you can't look away."
The delay in making a decision on hepatitis B shots is expected to be made public after Friday's meeting, and will likely face opposition from medical groups and experts who are concerned about the potential consequences for public health.
The Advisory Committee on Immunization Practices, led by US Health Secretary Robert F. Kennedy Jr., has delayed a decision on whether newborns should receive the hepatitis B vaccine on their first day of life, citing concerns about voting language and limited safety studies.
For decades, the government has advised that all babies be vaccinated against hepatitis B at birth, a strategy widely regarded as a public health success in preventing thousands of illnesses. However, Kennedy's committee is now considering whether to recommend the birth dose only for babies whose mothers test positive for the virus, which would mark a return to a strategy abandoned over three decades ago.
The move has sparked controversy among medical groups and experts, who argue that the delay could lead to increased cases of chronic hepatitis B infections in infants. According to the Centers for Disease Control and Prevention (CDC), 90% of infants who contract hepatitis B go on to develop chronic infections.
The committee's decision is also seen as a departure from established guidelines, which advise a dose within 24 hours of birth for all medically stable infants weighing at least 4.4 pounds. The new language, which would be voted on Friday, suggests that vaccination series should begin when the child is 2 months old if parents decide not to get a birth dose.
Kennedy's leadership of the committee has been criticized by medical groups, who argue that his anti-vaccine stance and appointment of several anti-vaccine voices to the panel have compromised the agency's credibility. The committee has made several decisions in recent months that have angered major medical groups, including recommending the removal of a preservative from flu vaccines and restricting a combination shot that protects against multiple diseases.
The delay in making a decision on hepatitis B shots comes as the US is experiencing a surge in vaccine-preventable diseases, including measles and COVID-19. Experts warn that the move could embolden anti-vaccine groups and undermine public health efforts to protect vulnerable populations.
"It's like watching a train wreck in slow motion," said Dr. Jason M. Goldman, president of the American College of Physicians. "You know it's going to end badly, but you can't look away."
The delay in making a decision on hepatitis B shots is expected to be made public after Friday's meeting, and will likely face opposition from medical groups and experts who are concerned about the potential consequences for public health.